Table 1 Clinical-pathological characteristics of 913 primary PCa patients by first metastatic progression
Parameter at diagnosis | No recist progression N (%) | First recist progression N (%) | P-value |
|---|---|---|---|
Age (years) | |||
< 50 | 6 (0.8) | 2 (1.5) | 0.036* |
≥ 50 and <60 | 106 (13.6) | 29 (21.3) | |
≥ 60 and <75 | 570 (73.4) | 97 (71.3) | |
≥ 75 and <80 | 80 (10.3) | 8 (5.9) | |
≥ 80 | 15 (1.9) | 0 | |
Stage | |||
T1 | 175 (22.6) | 12 (9) | < 0.001* |
T2 | 337 (43.5) | 27 (20.1) | |
T3 | 254 (32.8) | 88 (65.7) | |
T4 | 9 (1.1) | 7 (5.2) | |
Missing | 2 | 2 | |
Lymph nodes | |||
Negative | 725 (94.4) | 111 (83.5) | < 0.001* |
Positive | 43 (5.6) | 22 (16.5) | |
Missing | 9 | 3 | |
PSA (ng/ml) | |||
< 10 | 329 (43.6) | 40 (38.5) | 0.001* |
≥ 10 and <20 | 282 (37.3) | 28 (26.9) | |
> 20 | 144 (19.1) | 36 (34.6) | |
Missing | 22 | 32 | |
Gleason Score | |||
3–6 | 238 (32) | 18 (16.8) | < 0.001* |
7 | 326 (43.8) | 37 (34.6) | |
8–10 | 180 (24.2) | 52 (48.6) | |
Missing | 33 | 29 | |
Total (N) | 777 | 136 | |